Free Trial
NASDAQ:PETV

PetVivo Q1 2025 Earnings Results & Report

PetVivo logo
$0.56 -0.02 (-3.79%)
As of 03:12 PM Eastern

PetVivo reported Q1 2025 earnings on August 14, 2024. The company reported EPS of -$0.11, while revenue was $120 thousand.

Earnings Announcement Details

Quarter
Q1 2025
Report Date

PetVivo EPS Results

Actual EPS
-$0.11
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PetVivo Revenue Results

Actual Revenue
$120 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

PetVivo's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

PetVivo Q1 2025 Earnings FAQ

PetVivo (NASDAQ:PETV) reported earnings of -$0.11 per share for Q1 2025. The report was announced on Wednesday, August 14, 2024.

PetVivo reported revenue of $120 thousand for Q1 2025.

PetVivo's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for PetVivo on the company's earnings history page.

PetVivo Earnings Headlines

Black Friday Bombshell (for traders)
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Jaime Pickett Joins PetVivo Holdings, Inc. Board of Directors
Michael Handley Joins PetVivo Holdings, Inc. Board of Directors
See More PetVivo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PetVivo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetVivo and other key companies, straight to your email.

About PetVivo

PetVivo (NASDAQ:PETV) is a biomedical company focused on developing and commercializing medical therapeutics and devices for use in animals and, potentially, humans. The company’s technologies are designed to address conditions involving damaged or diseased tissue, with an emphasis on minimally invasive treatments.

PetVivo’s principal commercial product is Spryng with OsteoCushion Technology, an injectable product administered by veterinary professionals. It is intended to help manage lameness associated with osteoarthritis and other joint-related conditions in animals, including dogs and horses. The company continues to develop additional products based on its proprietary platform for regenerative and tissue-support applications.

Based in Minneapolis, Minnesota, PetVivo primarily serves the veterinary healthcare market through animal-health professionals and related distribution channels. John Lai serves as the company’s chief executive officer. The company has also indicated that its technologies may have future applications in human healthcare, subject to further development and regulatory approval.

View PetVivo Profile